Aller directement au contenu principal

Rédiger un PREreview

ANXA2P2 and PA2G4P4 Pseudogenes Are Associated with the Response to Ionizing Radiation and Could Be Used as Potential Biomarkers: In Silico Study

Publié
Serveur de preprints
Preprints.org
DOI
10.20944/preprints202512.2795.v1

Background: Head and neck squamous cell carcinomas (HNSCC) are aggressive malignancies with high mortality and poor prognosis. Pseudogenes with altered expression during HNSCC progression may serve as potential biomarkers for early detection, prognosis, and therapy selection. Methods: In this report, we analyzed the expression of ANXA2P2 and PA2G4P4 pseudogenes in HNSCC patients using data from The Cancer Genome Atlas. Clinical correlations were assessed through UALCAN and cBioPortal. Functional enrichment was investigated using REACTOME, ESTIMATE, and Gene Set Enrichment Analysis. Statistical analyses were performed with GraphPad Prism 8. Results: Both ANXA2P2 and PA2G4P4 were significantly upregulated in HNSCC compared to normal tissue. Their expression varied based on HPV status and was negatively correlated with overall survival. High pseudogene expression was associated with dysregulated oncogenic pathways, while low expression was linked to distinct immunological profiles. Conclusions: ANXA2P2 and PA2G4P4 exhibit oncogenic properties in HNSCC and hold potential as diagnostic and prognostic biomarkers.

Vous pouvez rédiger un PREreview de ANXA2P2 and PA2G4P4 Pseudogenes Are Associated with the Response to Ionizing Radiation and Could Be Used as Potential Biomarkers: In Silico Study. Un PREreview est une évaluation d'un preprint et peut varier de quelques phrases à un rapport détaillé, semblable à un rapport d'évaluation par les pairs organisé par une revue.

Avant de commencer

Nous vous demanderons de vous connecter avec votre identifiant ORCID iD. Si vous n'en avez pas, vous pouvez en créer un.

Qu’est-ce qu’un ORCID iD ?

Un ORCID iD est un identifiant unique qui vous distingue de toute personne ayant le même nom ou nom similaire.

Commencer maintenant